|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists.
|
30836160 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of SUV39H1 leads to transcriptional activation of these genes, especially RIG-I, followed by increased IFNβ and λ<sub>1</sub> production after poly(dA:dT) or RIG-I agonist M8 transfection, Collectively, our findings provide new evidence that the E7 oncoprotein plays a central role in dampening host innate immunity and raise the possibility that targeting the downstream effector SUV39H1 or the RIG-I pathway may be a viable strategy to treat viral and neoplastic disease.<b>IMPORTANCE</b> High-risk HPVs are major viral human carcinogens responsible for approximately 5% of all human cancers.
|
31776268 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated the therapeutic potential of systemic RIG-I activation by short 5'-triphosphate-modified RNA (ppp-RNA) for the treatment of acute myeloid leukemia (AML) in the syngeneic murine C1498 AML tumor model. ppp-RNA treatment significantly reduced tumor burden, delayed disease onset and led to complete remission including immunological memory formation in a substantial proportion of animals.
|
31740809 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We conclude that high RIG-I expression associates with poor outcome in OC, which is explainable by local immunosuppression in the tumor bed.
|
31800094 |
2020 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Specifically, we demonstrate that DRH-1/RIG-I is required for inducing the IPR in response to Orsay virus infection, but not in response to other triggers like microsporidian infection or proteotoxic stress.
|
31619561 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists.
|
30836160 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we present comprehensive data validating the concept and utility of treatment with synthetic RIG-I agonist ppp-RNA for the therapy of human cancer, with melanoma as potential entry indication amenable to intratumoral treatment.
|
31515294 |
2019 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Induction of Selenoprotein P mRNA during Hepatitis C Virus Infection Inhibits RIG-I-Mediated Antiviral Immunity.
|
30974086 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Retinoic acid-inducible gene-I (RIG-I)-like receptors and Toll-like receptors are the main pattern recognition receptors that recognize HCV pathogen-associated molecular patterns.
|
31027278 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these data reveal that the NS4A Y16 residue regulates a noncanonical Riplet-TBK1-IRF3-dependent, but RIG-I-MAVS-independent, signaling pathway that limits HCV infection.<b>IMPORTANCE</b> The HCV NS3-NS4A protease complex facilitates viral replication by cleaving and inactivating the antiviral innate immune signaling proteins MAVS and Riplet, which are essential for RIG-I activation.
|
31534039 |
2019 |
|
Influenza
|
0.100 |
Biomarker
|
disease |
BEFREE |
A better understanding of RIG-I sensing of IAV infection provides insight into the development of novel interventions to combat influenza virus infection.
|
30602605 |
2019 |
|
Influenza
|
0.100 |
Biomarker
|
disease |
BEFREE |
LEP and DPEP have certain protective effects on the influenza virus-infected mice, which may be associated with their abilities of effectively alleviating lung injury, improving the immunologic function of infected mice and adjusting the host's TLRs and RIG-1 pathways.
|
31551774 |
2019 |
|
Influenza
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rli32-induced IFN-β response is RIG-I (retinoic acid inducible gene I) dependent, and cells primed with rli32 inhibit influenza virus replication.
|
31594810 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we present comprehensive data validating the concept and utility of treatment with synthetic RIG-I agonist ppp-RNA for the therapy of human cancer, with melanoma as potential entry indication amenable to intratumoral treatment.
|
31515294 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Phospholipase A and acyltransferase 4 (PLAAT4) is a member of the HREV107 tumor suppressor gene family.
|
31131438 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aimed to find out the molecular therapeutic effect of lipo-ATRA on tumour suppressor TIG3 and cell proliferative biomarker PPARγ in B (a) P-induced lung cancer model.
|
31300983 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell-intrinsic activation of the RNA receptor retinoic acid-inducible gene-I (RIG-I) can trigger an immunogenic form of programmed tumor cell death, but its impact on antitumor responses remains largely unexplored.
|
30906666 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistently, therapeutic targeting of RIG-I with 5'- triphosphorylated RNA in both tumor and nonmalignant host cells potently augmented the efficacy of CTLA-4 checkpoint blockade in several preclinical cancer models.
|
31519811 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RIG-I-knocked-down HCC cells showed upregulated expression of stem cell marker genes, enhanced secretion of factors suppressing in vitro generation of DCs into the conditioned medium (CM), and induction of a phenotype of tumor-infiltrating DCs (TIDCs) with low levels of DC markers in their tumors in nude mice.
|
31088527 |
2019 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results show that the small RIG-I activator 3p10LG9 can confer short-term protection against DENV and can be further explored as an antiviral treatment in humans.<b>IMPORTANCE</b> Short hairpin RNA ligands that activate RIG-I induce antiviral responses in infected cells and prevent or control viral infections.
|
31043531 |
2019 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A better understanding of RIG-I sensing of IAV infection provides insight into the development of novel interventions to combat influenza virus infection.
|
30602605 |
2019 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, little is known about the biological behaviors of Rig-I devoid of viral infection.
|
31595820 |
2019 |
|
Virus Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RIG-I (Retinoic acid-inducible gene I) and MDA5 (Melanoma Differentiation-Associated protein 5), collectively known as the RIG-I-like receptors (RLRs), are key protein sensors of the pathogen-associated molecular patterns (PAMPs) in the form of viral double-stranded RNA (dsRNA) motifs to induce expression of type 1 interferons (IFN1) (IFNα and IFNβ) and other pro-inflammatory cytokines during the early stage of viral infection.
|
31379819 |
2019 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistically, Lnczc3h7a binds to both TRIM25 and activated RIG-I, serving as a molecular scaffold for stabilization of the RIG-I-TRIM25 complex at the early stage of viral infection.
|
31036902 |
2019 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
DHX15 associates with RIG-I caspase activation and recruitment domains (CARDs) through its amino terminus, in which the complex is recruited to MAVS on virus infection.
|
31090472 |
2019 |